PD-L1 Protein (AA 18-238) (His tag)

N° du produit ABIN7321268

Protéine Recombinant PD-L1 exprimée dans HEK-293 Cells.

Aperçu rapide pour PD-L1 Protein (AA 18-238) (His tag) (ABIN7321268)

Antigène: PD-L1 (CD274 (PD-L1))

Type de proteíne: Recombinant

Origine: Rat

Source: HEK-293 Cells

Pureté: > 95 % as determined by reducing SDS-PAGE.

Détail du produit

Attributs du protein: AA 18-238

Purification/Conjugué: Cette PD-L1 protéine est marqué à la His tag.

Fonction: Recombinant Rat PD-L1/B7-H1/CD274 Protein (C-His)

Séquence: Ala18-Thr238

Attributs du produit: Recombinant Rat PD-L1 is produced by our Mammalian expression system and the target gene encoding Ala18-Thr238 is expressed with a 6His tag at the C-terminus.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1/B7-H1/CD274

Sujet: B7-H,B7-H1,B7H1,PD-L1,PDCD1L1,PDCD1LG1,PDL1,CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

Poids moléculaire:

Calculated MW: 26.1 kDa

Observed MW: 40-60 kDa

UniProt: D4AE25

Pathways: Cancer Immune Checkpoints